{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T18:59:25Z","timestamp":1759777165713,"version":"3.41.2"},"reference-count":9,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>C-reactive protein (CRP) apheresis has been introduced in ST-elevation myocardial infarction and cardiogenic shock. Here, we describe a first-in-man application in non-ST-elevation acute coronary syndrome (NSTE-ACS). Seven NSTE-ACS patients with high CRP levels (range 14.2\u2013154\u2005mg\/L) were treated with CRP apheresis. Treatment was well-tolerated. Patients were discharged in good clinical condition.<\/jats:p>","DOI":"10.3389\/fcvm.2024.1401566","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T04:24:00Z","timestamp":1723695840000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: C-reactive protein apheresis in non-ST-elevation ACS\u2014case series from the C-reactive protein apheresis in Acute Myocardial Infarction Registry"],"prefix":"10.3389","volume":"11","author":[{"given":"J.","family":"Torzewski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Mattecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Heigl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sheriff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"591714","DOI":"10.3389\/fcvm.2021.591714","article-title":"C-reactive protein apheresis as anti-inflammatory therapy in acute myocardial infarction: results of the CAMI-1 study","volume":"8","author":"Ries","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1286710","DOI":"10.3389\/fddsv.2023.1286710","article-title":"Case report: C-reactive protein apheresis in cardiogenic shock: case series from the C-reactive protein apheresis in acute myocardial infarction-registry","volume":"3","author":"Torzewski","year":"2023","journal-title":"Front Drug Discov"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3390\/jcm11071771","article-title":"Targeting C-reactive protein by selective apheresis in humans: pros and cons","volume":"11","author":"Torzewski","year":"2022","journal-title":"J Clin Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4767105","DOI":"10.1155\/2018\/4767105","article-title":"\u201cFirst in man\u201d: case report of selective C-reactive protein apheresis in a patient with acute ST segment elevation myocardial infarction","volume":"2018","author":"Ries","year":"2018","journal-title":"Case Rep Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"925020","DOI":"10.12659\/AJCR.925020","article-title":"First-in-Man: case report of selective C-reactive protein apheresis in a patient with SARS-CoV-2 infection","volume":"21","author":"Torzewski","year":"2020","journal-title":"Am J Case Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3390\/jcm11071956","article-title":"Seven COVID-19 patients treated with C-reactive protein (CRP) apheresis","volume":"11","author":"Esposito","year":"2022","journal-title":"J Clin Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.3390\/biomedicines11082279","article-title":"Being eaten alive: how energy-deprived cells are disposed of, mediated by C-reactive protein-including a treatment option","volume":"11","author":"Sheriff","year":"2023","journal-title":"Biomedicines"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fddsv.2024.1338535","article-title":"A short review on CRP synthesis inhibition in cardiovascular disease","volume":"4","author":"Zaczkiewicz","year":"2024","journal-title":"Front Drug Discov"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1401566\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T04:24:02Z","timestamp":1723695842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1401566\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":9,"alternative-id":["10.3389\/fcvm.2024.1401566"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1401566","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2024,8,15]]},"article-number":"1401566"}}